The burgeoning field of metabolic disease management is witnessing a novel convergence of therapies. Tirzepatide , a dual GIP/GLP-1 receptor agonist , alongside Surfactant , a triple GIP/GLP-1/GCG receptor agonist , https://pukkabookmarks.com/story21694484/tirzepatide-and-nmn-a-combined-approach-to-physiological-health